Avalyn Pharma found strong investor interest in its inhalable drugs in development for two types of pulmonary fibrosis, enabling the company to upsize its IPO. Data from two mid-stage studies are expected in 2027.

The post Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials appeared first on MedCity News.

FibroGen drug pamrevlumab has failed a Phase 3 study testing it in the chronic lung disorder idiopathic pulmonary fibrosis. It’s the second trial failure for the drug in the past month and the company’s third Phase 3 failure in the past two months.

The post FibroGen’s Fibrosis Drug Flunks Again in Phase 3, Triggering Cost-Cutting Moves appeared first on MedCity News.

The biggest rounds of recent biotech financings are from startups raising money to advance their research to the clinic. Here’s a look back at funding rounds from companies such as Abdera Therapeutics, Complement Therapeutics, and Enveda Biosciences.

The post Biotech Financing Roundup: Envedo Bio, Complement, Abdera, TORL & More appeared first on MedCity News.

Three months after Alentis Therapeutics’ lead program posted positive Phase 1 data, the biotech has raised cash to advance that program to mid-stage testing in fibrosis. The Series C financing will also support a cancer drug candidate ready to start human testing.

The post Alentis Therapeutics Lands $105M for Clinical Trials in Fibrosis and Cancer appeared first on MedCity News.

Capstan Therapeutics, a University of Pennsylvania spinout, is now out of stealth with technology that could enable new medicines that work by engineering cells inside of a patient. Penn biotech pioneers Carl June and Drew Weissman are among the scientific co-founders of this startup, which aims to develop therapies for fibrosis, cancer, inflammation, and genetic diseases.

The post Penn spinout Capstan aims for next cell therapy frontier: in vivo cell engineering appeared first on MedCity News.

Sonata Therapeutics is developing drugs that reprogram cellular microenvironments to send signals intended to have curative effects. Cancer is the initial focus of the biotech, which Flagship Pioneering formed by combining two of its preclinical portfolio companies.

The post Flagship merges two of its biotechs to form cellular microenvironment-focused Sonata appeared first on MedCity News.

Roche will provide $390 million in cash upfront and then provide milestone payments to acquire Promedior, which is developing a drug to treat a rare and fatal lung disease.

The post After BMS walked away from Promedior, Roche to acquire the fibroid-treatment firm for $1.4B appeared first on MedCity News.

Venture capital firm Versant Ventures launched the company with a $20 million Series A funding round last year.

The post Preclinical startup Jecure makes bee-line to exit with Genentech buyout appeared first on MedCity News.

The Waltham, Massachusetts-based company will receive $100 million, in addition to potential undisclosed milestones and royalties.

The post Morphic partners with investor AbbVie on integrin inhibitor development appeared first on MedCity News.

Firm raises funding for RNAi therapy’s clinical development from group of Chinese funds.

The post Sirnaomics raises $25 million in Series C1 round for RNAi drug appeared first on MedCity News.

Biopharma vet Deborah Dunsire has joined Waltham, Massachusetts-based XTuit Pharmaceuticals, a startup targeting the microenvironments that protect and drive certain cancers and fibrotic diseases.

The post From Big Pharma to nascent startup, Deborah Dunsire joins XTuit appeared first on MedCity News.

The post Third Rock funnels $45M into Pliant Therapeutics to develop small molecule drugs for fibrosis appeared first on MedCity News.

The post Five (non-cancer) areas Bristol-Myers Squibb is pursuing hard appeared first on MedCity News.